Chardan lowered the firm’s price target on Intellia Therapeutics (NTLA) to $88 from $94 and keeps a Buy rating on the shares after ...
Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price ...
Check out the highest-rated Korean horror-comedy shows that will entertain K-drama fans with the right dose of thrill and ...